Emanuel Bührer
European Organisation for Research and Treatment of Cancer(BE)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Testicular diseases and treatments, Melanoma and MAPK Pathways, Cutaneous Melanoma Detection and Management, Lymphoma Diagnosis and Treatment
Most-Cited Works
- → Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial(2024)11 cited
- → Metastatic Potential of Small Testicular Germ Cell Tumors: Implications for Surveillance of Small Testicular Masses(2022)10 cited
- → Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced BRAF-V600E/K-mutated melanoma: The primary analysis of an EORTC randomized phase II study (EBIN).(2024)8 cited
- → Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study(2025)8 cited
- → Challenges in the diagnosis of marginal zone lymphoma with symptoms of small intestinal disease: a case report and scoping review of the literature(2022)7 cited
- → Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium(2024)4 cited
- → Swiss germ-cell cancer consensus recommendations(2021)2 cited
- → 351TiP EORTC BCG 1984 – NOBLE: Noeoadjuvant olaparib and durvalumab for patients with BRCA-associated triple-negative breast cancer(2023)1 cited
- → Impact of Teratoma on Survival Probabilities of Patients with Metastatic Non-Seminomatous Germ Cell Cancer(2024)
- → Capturing the true effect of anti-PD-1 therapy on patients’ health-related quality of life – Authors' reply(2024)